Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results

Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).

The condition often comes alongside disorders such as Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure. While the drug did not show improvement in the overall participant population, a subset of patients with MSA met primary endpoints.